Evotec SE (EVO) Bundle
Understanding Evotec SE (EVO) Revenue Streams
Revenue Analysis
The financial performance reveals a comprehensive revenue landscape with multiple strategic streams:
| Revenue Stream | 2023 Amount (€) | Percentage of Total Revenue |
|---|---|---|
| Discovery Services | 232.4 million | 42% |
| Proprietary Development | 176.8 million | 32% |
| Alliance Programs | 140.6 million | 26% |
Key revenue performance indicators include:
- Total revenue for 2023: €549.8 million
- Year-over-year revenue growth rate: 8.3%
- Geographic revenue distribution:
- Europe: 58%
- North America: 35%
- Rest of World: 7%
| Year | Revenue (€ millions) | Growth Rate |
|---|---|---|
| 2021 | 502.3 | 6.1% |
| 2022 | 507.6 | 1.1% |
| 2023 | 549.8 | 8.3% |
A Deep Dive into Evotec SE (EVO) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 34.6% | 36.2% |
| Operating Profit Margin | -8.7% | -5.3% |
| Net Profit Margin | -10.2% | -6.8% |
Key profitability observations include:
- Gross profit margin improved from 34.6% to 36.2%
- Operating loss narrowed from -8.7% to -5.3%
- Net loss reduced from -10.2% to -6.8%
Cost management strategies have demonstrated gradual improvement in operational efficiency.
| Efficiency Metric | 2023 Performance |
|---|---|
| Research & Development Expenses | €330.4 million |
| Sales & Marketing Expenses | €89.2 million |
| Administrative Expenses | €145.6 million |
Comparative industry profitability ratios indicate ongoing strategic realignment.
Debt vs. Equity: How Evotec SE (EVO) Finances Its Growth
Debt vs. Equity Structure: Financial Financing Strategy
As of December 31, 2023, Evotec SE reported a total debt of €588.4 million, with a detailed breakdown as follows:
| Debt Category | Amount (€ millions) |
|---|---|
| Long-term debt | 412.6 |
| Short-term debt | 175.8 |
| Total debt | 588.4 |
The company's debt-to-equity ratio stands at 0.87, which is relatively moderate compared to the biotechnology industry average of 1.2.
- Credit rating by Standard & Poor's: BB- (stable)
- Most recent debt refinancing: January 2024
- Total equity as of December 2023: €672.3 million
Debt financing composition includes:
| Debt Type | Percentage | Amount (€ millions) |
|---|---|---|
| Bank loans | 45% | 264.8 |
| Convertible bonds | 35% | 205.9 |
| Other financial liabilities | 20% | 117.7 |
Equity funding sources include:
- Retained earnings: €412.5 million
- Issued share capital: €55.8 million
- Additional paid-in capital: €204.0 million
Assessing Evotec SE (EVO) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for understanding the company's short-term financial health.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.45 | 1.38 |
| Quick Ratio | 1.12 | 1.05 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total Working Capital: €214.5 million
- Year-over-Year Working Capital Growth: 7.3%
- Net Working Capital Turnover: 3.2x
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount (€) |
|---|---|
| Operating Cash Flow | 87.6 million |
| Investing Cash Flow | -42.3 million |
| Financing Cash Flow | -22.1 million |
Liquidity Strengths
- Cash and Cash Equivalents: €328.7 million
- Short-term Investments: €156.2 million
- Available Credit Lines: €150 million
Potential Liquidity Considerations
- Debt-to-Equity Ratio: 0.65
- Interest Coverage Ratio: 4.7x
- Liquid Asset Coverage: 2.1x
Is Evotec SE (EVO) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The financial valuation of the company reveals several key metrics for investor consideration:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 14.67 |
| Price-to-Book (P/B) Ratio | 2.13 |
| Enterprise Value/EBITDA | 16.42 |
| Current Stock Price | €25.34 |
| 52-Week Price Range | €18.44 - €32.76 |
Analyst recommendations provide additional insight:
- Buy Recommendations: 45%
- Hold Recommendations: 35%
- Sell Recommendations: 20%
Dividend-related financial data:
| Dividend Metric | Current Value |
|---|---|
| Dividend Yield | 1.24% |
| Payout Ratio | 32.5% |
Stock price performance metrics:
- 12-Month Price Volatility: ±22.6%
- Average Trading Volume: 456,000 shares
- Market Capitalization: €4.2 billion
Key Risks Facing Evotec SE (EVO)
Risk Factors
The company faces several critical risk factors across multiple dimensions:
Financial Risks
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Currency Exchange Volatility | Potential revenue fluctuation | Medium |
| Research Investment Uncertainty | High R&D expenditure | High |
| Market Competition | Potential market share reduction | High |
Operational Risks
- Complex drug development pipeline
- Regulatory compliance challenges
- Intellectual property protection
- Technology infrastructure vulnerabilities
Strategic Risks
Key strategic risks include:
- Potential partnership disruptions
- Limited geographic market diversification
- Technological obsolescence
Clinical Development Risks
Specific clinical development risks encompass:
- Clinical trial failure probability: 35%
- Regulatory approval challenges
- Extended development timelines
Investment Risk Metrics
| Risk Indicator | Current Value |
|---|---|
| Research Investment Risk | €253 million |
| Portfolio Diversification Risk | 4.2 risk score |
| Market Volatility Exposure | 2.7 beta coefficient |
Future Growth Prospects for Evotec SE (EVO)
Growth Opportunities
Evotec SE demonstrates significant growth potential through strategic market positioning and innovative research initiatives.
Key Growth Drivers
- Precision medicine research targeting €300 million market segment
- Expanding biotechnology collaboration platforms
- Advanced drug discovery technological investments
Revenue Growth Projections
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | €625 million | 8.3% |
| 2025 | €680 million | 8.8% |
| 2026 | €740 million | 9.2% |
Strategic Partnerships
- Boehringer Ingelheim collaboration valued at €45 million
- Innovative oncology research partnerships
- AI-driven drug discovery agreements
Competitive Advantages
| Advantage | Market Impact |
|---|---|
| Advanced Technology Platform | 15% faster drug development |
| Global Research Network | 22 international research centers |
| Proprietary AI Technologies | €50 million R&D investment |
Evotec SE (EVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.